These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7863274)

  • 41. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica.
    Kimura M; Tokuda Y; Oshiawa H; Yoshida K; Utsunomiya M; Kobayashi T; Deshpande GA; Matsui K; Kishimoto M
    J Rheumatol; 2012 Jan; 39(1):148-53. PubMed ID: 22174210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica].
    Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T
    Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.
    Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C
    Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroid requirements in polymyalgia rheumatica.
    Weyand CM; Fulbright JW; Evans JM; Hunder GG; Goronzy JJ
    Arch Intern Med; 1999 Mar; 159(6):577-84. PubMed ID: 10090114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
    Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
    Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data.
    Pamuk ON; Dönmez S; Karahan B; Pamuk GE; Cakir N
    Clin Exp Rheumatol; 2009; 27(5):830-3. PubMed ID: 19917168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymyalgia rheumatica can recur years after discontinuation of corticosteroid therapy.
    Docken WP
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S25-7. PubMed ID: 19646342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymyalgia rheumatica.
    Lestico MR; Boh LE; Schuna AA
    Clin Pharm; 1993 Aug; 12(8):571-80. PubMed ID: 8222521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.
    Burkel M; Arndt F; Schirmer JH; Moosig F; Holle JU
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):94-97. PubMed ID: 27974093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
    Pountain GD; Calvin J; Hazleman BL
    Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Polymyalgia rheumatica].
    Duftner C; Dejaco C; Schirmer M
    Internist (Berl); 2009 Jan; 50(1):51-7; quiz 58-9. PubMed ID: 19099273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.
    Cleuziou C; Binard A; De Bandt M; Berthelot JM; Saraux A
    J Rheumatol; 2012 Feb; 39(2):310-3. PubMed ID: 22174199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
    Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment.
    Macchioni P; Boiardi L; Meliconi R; Salvarani C; Grazia Uguccioni M; Rossi F; Pulsatelli L; Facchini A
    J Rheumatol; 1994 Oct; 21(10):1860-4. PubMed ID: 7837151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
    Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Favorable role of interleukin 10 in patients with polymyalgia rheumatica.
    Straub RH; Herfarth HH; Rinkes B; Konecna L; Glück T; von Landenberg P; Georgi J; Helmke K; Schölmerich J; Vaith P; Lang B
    J Rheumatol; 1999 Jun; 26(6):1318-25. PubMed ID: 10381050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
    Narváez J; Nolla-Solé JM; Clavaguera MT; Valverde-García J; Roig-Escofet D
    J Rheumatol; 1999 Sep; 26(9):1945-52. PubMed ID: 10493675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR).
    Lee JH; Choi ST; Kim JS; Yoon BY; Kwok SK; Kim HS; Kim YS; Song JS; Lee SH; Kim HR
    Rheumatol Int; 2013 Jun; 33(6):1475-80. PubMed ID: 23184033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.
    Ma X; Yang F; Wu J; Xu B; Jiang M; Sun Y; Sun C; Yu Y; Xu D; Xiao L; Ren C; Chen C; Ye Z; Liang J; Lin J; Chen W
    PLoS Med; 2023 Jun; 20(6):e1004249. PubMed ID: 37384596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.